Dr. Reddy's to release Q4 and full year FY 20 results on May 20, 2020
07 May 2020 - 6:50PM
Business Wire
Earnings call slated for May 20 @ 5:15 PM
IST / 7:45 AM EDT
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) will announce results for the fourth quarter and full year
ended March 31, 2020 on Wednesday, May 20, 2020 after the Board
Meeting.
Summary of Events
Event
Date and Time
Medium
Release of financial results
May 20th, after the Board
Meeting
Stock Exchange, Media, Company
website, Business wire, Email
Press meet presentation
Will be available on the
Company’s website
Company’s website
www.drreddys.com
Earnings Call
May 20th, 5:15 PM IST / 7:45 AM
EDT
Hosted by the Company (Details
below)
Playback of Earnings Call
After the earnings call till May
27th, 2020
Details below
Transcript of the Earnings
call
Will be available on the
Company’s website
URL available on Company’s
website, www.drreddys.com
Earnings Call
Following the release, the management of the Company will host
an earnings call to discuss the Company’s financial performance.
(Dial In and other details given below)
Play Back
The play back will be available after the earnings call, till
May 27th, 2020. For play back dial in phone No: +91 22 7194 5757 |
+91 22 6663 5757, and Playback Code is 74886.
Conference Dial-In
Numbers
Universal Access Number:
+91 22 6280 1219
+91 22 7115 8120
Local Access Number:
Available all over India
+91 70456 71221
International Toll Free
Number:
USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448
No password/pin number is necessary to dial in to any of the
above numbers. The operator will provide instructions on asking
questions before and during the call.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr Reddy’s operates in
markets across the globe. Our Major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on
the management’s current views and assumptions and involve known or
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. In addition to statements which are
forward-looking by reason of context, the words "may", "will",
"should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar
expressions identify forward-looking statements. Actual results,
performance or events may differ materially from those in such
statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200507005403/en/
INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph:
+91-40-49002135)
MEDIA RELATIONS APARNA TEKURI aparnatekuri@drreddys.com (PH:
+91-40-49002446)
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2024 to May 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2023 to May 2024